Simridarlimab
Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro[1].
Product Specifications
CAS Number
[2378862-90-7]
Product Name Alternative
IBI-322
UNSPSC
12352203
Target
CD47; PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/simridarlimab.html
Purity
99.81
Solubility
10 mM in DMSO
Smiles
[Simridarlimab]
Molecular Weight
(125.734 kDa)
References & Citations
[1]CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunol Immunother. 2021 Feb;70 (2) :365-376.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Neisseria meningitidis serogroup C UPF0756 membrane protein NMCC_1816 (NMCC_1816), partial
